Global Hemophilia Market

Hemophilia Market Size, Share, Growth Analysis, By Disease(Hemophilia A, hemophilia B, and others), By Product(Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and others), By Therapy(As Replacement Therapy, Gene Therapy, and others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35D2191 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 90 | Figures: 76

Hemophilia Market Competitive Landscape

The market for hemophilia is characterized by moderate competitiveness and is dominated by a few major players. These key players have engaged in various strategic alliances such as acquisitions, collaborations, and the introduction of advanced products and research studies to establish their position in the global market.

Hemophilia Market Top Player’s Company Profiles

  • Bayer AG (Germany)
  • BioMarin Pharmaceutical Inc. (United States)
  • CSL Behring (Australia)
  • Kedrion (Italy)
  • Novo Nordisk (Denmark)
  • Pfizer Inc. (United States)
  • Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
  • Sanofi (Genzyme Corporation) (France/United States)
  • Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
  • Grifols (Spain)
  • Octapharma (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Biogen (United States)
  • Baxalta (United States)
  • LFB Group (France)
  • Bioverativ Inc. (United States)
  • Bio Products Laboratory Ltd. (United Kingdom)
  • Kogenate (Germany)
  • Sangamo Therapeutics, Inc. (United States)
  • Spark Therapeutics (United States)

Hemophilia Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Hemophilia Market size was valued at USD 12.6 billion in 2022 and is poised to grow from USD 13.43 billion in 2023 to USD 23.39 billion by 2031, at a CAGR of 6.6% during the forecast period (2024-2031).

The market for hemophilia is characterized by moderate competitiveness and is dominated by a few major players. These key players have engaged in various strategic alliances such as acquisitions, collaborations, and the introduction of advanced products and research studies to establish their position in the global market. 'Bayer AG (Germany)', 'BioMarin Pharmaceutical Inc. (United States)', 'CSL Behring (Australia)', 'Kedrion (Italy)', 'Novo Nordisk (Denmark)', 'Pfizer Inc. (United States)', 'Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)', 'Sanofi (Genzyme Corporation) (France/United States)', 'Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)', 'Grifols (Spain)', 'Octapharma (Switzerland)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Biogen (United States)', 'Baxalta (United States)', 'LFB Group (France)', 'Bioverativ Inc. (United States)', 'Bio Products Laboratory Ltd. (United Kingdom)', 'Kogenate (Germany)', 'Sangamo Therapeutics, Inc. (United States)', 'Spark Therapeutics (United States)'

Advances in gene therapy, recombinant factor concentrates, and personalized medicine have significantly improved treatment options for hemophilia, enhancing patient outcomes and quality of life.

One key market trend in the hemophilia market is the growing adoption of gene therapy. Gene therapy has shown significant promise in providing long-term solutions for hemophilia by addressing the underlying genetic cause of the disorder. This approach involves introducing functional genes into the patient's body to produce the missing clotting factors. Gene therapy for hemophilia has gained traction due to advancements in viral vector technologies and improved understanding of genetic engineering. Several clinical trials and research studies have demonstrated positive results, showcasing the potential for gene therapy to provide long-lasting benefits and reduce the burden of frequent treatments such as factor replacement therapy.

North America emerges as the dominating region in the global hemophilia market . With its advanced healthcare infrastructure, high awareness about hemophilia, and substantial investments in research and development, North America commands a significant share of the market. The region is home to key players, renowned medical institutions, and a well-established patient support system, which contribute to its leadership position. Furthermore, North America benefits from a strong regulatory framework and reimbursement policies that support access to advanced hemophilia treatments. These factors collectively position North America as the dominant region in the global hemophilia market .

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Hemophilia Treatment Market
Buy Now GET FREE SAMPLE
Hemostasis Products Market
Buy Now GET FREE SAMPLE
Hematology Market
Buy Now GET FREE SAMPLE
Hemp Market
Buy Now GET FREE SAMPLE
Hemostatic Agents Market
Buy Now GET FREE SAMPLE
Hemoglobinopathies Treatment Market
Buy Now GET FREE SAMPLE
Hematology Diagnostics Market
Buy Now GET FREE SAMPLE
Industrial Hemp Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Hemophilia Market

Report ID: SQMIG35D2191

$5,300
BUY NOW GET FREE SAMPLE